Wimonchat Tangamornsuksan

Wimonchat Tangamornsuksan

Auto-generated profile, based on publicly available information

Wimonchat Tangamornsuksan

Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2013 in JAMA Dermatology
Verified
Journal Article
Open access
PDF file
WTWimonchat Tangamornsuksan
Wimonchat Tangamornsuksan
NCNathorn Chaiyakunapruk
Nathorn Chaiyakunapruk
RSRatchadaporn Somkrua
Ratchadaporn Somkrua
MLManupat Lohitnavy
Manupat Lohitnavy
WTWichittra Tassaneeyakul
Wichittra Tassaneeyakul
Research from JAMA Dermatology — Relationship Between the HLA-B*1502 Allele and Carbamazepine-Induced Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis — A Systematic Review and Meta-analysis

14 August 2015 in PLOS ONE
Verified
Journal Article
Open access
PDF file
YNYuwadee Ngamwong
Yuwadee Ngamwong
WTWimonchat Tangamornsuksan
Wimonchat Tangamornsuksan
OLOrnrat Lohitnavy
Ornrat Lohitnavy
NCNathorn Chaiyakunapruk
Nathorn Chaiyakunapruk
CSC. Norman Scholfield
C. Norman Scholfield
MLManupat Lohitnavy
Manupat Lohitnavy
Smoking and asbestos exposure are important risks for lung cancer. Several epidemiological studies have linked asbestos exposure and smoking to lung cancer. To reconcile and unify these results, we conducted a systematic review and meta-analysis to provide a quantitative estimate of the increased risk of lung cancer associated with asbestos exposure and cigarette smoking and to classify their interaction. Five electronic databases were searched from inception to May, 2015 for observational studies on lung cancer. All case-control (N = 10) and cohort (N = 7) studies were included in the analysis. We calculated pooled odds ratios (ORs), relative risks (RRs) and 95% confidence intervals (CIs) using a random-effects model for the association of asbestos exposure and smoking with lung cancer. Lung cancer patients who were not exposed to asbestos and non-smoking (A-S-) were compared with; (i) asbestos-exposed and non-smoking (A+S-), (ii) non-exposure to asbestos and smoking (A-S+), and (iii) asbestos-exposed and smoking (A+S+). Our meta-analysis showed a significant difference in risk of developing lung cancer among asbestos exposed and/or smoking workers compared to controls (A-S-), odds ratios for the disease (95% CI) were (i) 1.70 (A+S-, 1.31–2.21), (ii) 5.65; (A-S+, 3.38–9.42), (iii) 8.70 (A+S+, 5.8–13.10). The additive interaction index of synergy was 1.44 (95% CI = 1.26–1.77) and the multiplicative index = 0.91 (95% CI = 0.63–1.30). Corresponding values for cohort studies were 1.11 (95% CI = 1.00–1.28) and 0.51 (95% CI = 0.31–0.85). Our results point to an additive synergism for lung cancer with co-exposure of asbestos and cigarette smoking. Assessments of industrial health risks should take smoking and other airborne health risks when setting occupational asbestos exposure limits.

1 April 2018 in JAMA Dermatology
Verified
Journal Article
Closed access
PDF file
WTWimonchat Tangamornsuksan
Wimonchat Tangamornsuksan
MLManupat Lohitnavy
Manupat Lohitnavy
Importance Dapsone-induced hypersensitivity syndrome (DHS) is a life-threatening adverse drug reaction. Based on available epidemiologic studies, HLA genotypes may play an important role in DHS. Objective To assess the association betweenHLA-B*1301and dapsone-induced cutaneous adverse drug reactions (cADRs). Data Sources Human studies investigating associations betweenHLA-B*1301and dapsone-induced cADRs were systematically searched without language restriction from the inception of each database until September 12, 2017, in PubMed, the Human Genome Epidemiology Network), and the Cochrane Library. Combinations ofHLA genotypes, dapsone,and synonymous terms were used; reference lists were searched in selected articles. Study Selection Two reviewers identified studies investigating the associations betweenHLA-B*1301and dapsone-induced cADRs that reported sufficient data for calculating the frequency ofHLA-B*1301carriers among case and control patients, in which all patients received dapsone beforeHLA-B*1301screening. An initial search of the databases identified 391 articles, of which 3 studies (2 in Chinese populations and 1 in a Thai population) met the inclusion criteria. Data Extraction and Synthesis Overall odds ratios (ORs) with 95% CIs were calculated using a random-effects model to determine the association betweenHLA-B*1301and dapsone-induced cADRs. Subgroup analyses by type of cADR were also performed. PRISMA guidelines were used to abstract and assess data. Main Outcomes and Measures Primary outcomes were associations betweenHLA-B*1301and dapsone-induced cADRs in dapsone-tolerant controls. The outcomes are reported as overall OR. Statistical heterogeneity was assessed using theQstatistic andI2tests. Results From the 3 included studies, there were 111 unique patients with dapsone-induced cADRs (subsequently used in the meta-analysis), 1165 dapsone-tolerant patients, and 3026 healthy controls. The cases included 64 men and 49 women (2 patients were missing from the meta-analysis; 1 each from 2 of the 3 studies); mean age was 39.7 years. An association betweenHLA-B*1301and dapsone-induced cADRs was identified (summary OR, 43.0; 95% CI, 24.0-77.2). Subgroup analyses among types of cADRs produced similar findings in DHS (OR, 51.7; 95% CI, 16.9-158.5), dapsone-induced severe cADRs (Stevens-Johnson syndrome and toxic epidermal necrolysis [SJS/TEN] plus drug rash [adverse skin reaction to a drug] along with eosinophilia and systemic symptoms [DRESS]) (OR, 54.0; 95% Cl, 8.0-366.2), dapsone-induced SJS/TEN (OR, 40.5; 95% CI, 2.8-591.0), and dapsone-induced DRESS (OR, 60.8; 95% CI, 7.4-496.2). There was no heterogeneity (I2= 0%,P= .38). Conclusions and Relevance Associations betweenHLA-B*1301and dapsone-induced cADRs were found in dapsone-tolerant and healthy control groups. For patient safety, genetic screening forHLA-B*1301in Asian populations before dapsone therapy is warranted.


25 January 2018 in Journal of Pharmacy & Pharmaceutical Sciences
Verified
Journal Article
Open access
PDF file
WTWimonchat Tangamornsuksan
Wimonchat Tangamornsuksan
CSC. Norman Scholfield
C. Norman Scholfield
MLManupat Lohitnavy
Manupat Lohitnavy
PURPOSE: To systematically review and quantitatively synthesize associations between HLA genotypes and oxcarbazepine-induced cutaneous adverse drug reactions (OXC-cADRs), including Stevens–Johnson syndrome (SJS) and maculopapular rash. METHODS: Studies investigating associations between HLA genotypes and OXC-cADRs were systematically searched irrespective of language, in PubMed, HuGENet (Human Genome Epidemiology Network), and the Cochrane Library from their inception until January, 2017. Inclusion criteria were studies investigating associations between HLA genotypes and OXC-cADRs that reported sufficient data for calculating the frequency of HLA genotype carriers among cases and controls. Overall odds ratios (ORs) with corresponding 95%CIs were calculated using a random-effects model to determine the association between HLA genotypes and OXC-cADRs. RESULTS: The initial searches identified 91 articles, of which 6 studies met the selection criteria. The studies included 229 patients with OXC-cADRs, 251 OXC-tolerant patients, and 2,358 participants from general populations of Han Chinese, Korean, and Thai ethnicities. Associations between HLA-B*1502 and OXC-induced SJS were found in both the general population [OR=30.2 (95%CI=3.45-264)] and in OXC-tolerant individuals [OR=26.4 (95%CI=7.98-87.6)]. An association between the HLA-B*1502 and OXC-induced maculopapular rash was found in the general population [OR=5.67 (95%CI=2.03-15.9)] while HLA-A*3101 also associated with OXC-induced maculopapular rash [overall OR=29.2 (95%CI=6.70-128)]. CONCLUSIONS: Strong associations between the HLA-B*1502 and OXC-cADRs (SJS and maculopapular rash) were found in both controls from general population and OXC-tolerant groups. There was also an association between HLA-B*3101 and OXC-induced maculopapular rash. For patient safety, genetic screening especially for HLA-B*1502 prior to OXC therapy at least in these closely related ethnicities is warranted. Further studies need to better define other ethnicities at risk and a wider range of MHC gene subtypes. This article is open to POST-PUBLICATION REVIEW. Registered readers (see “For Readers”) may comment by clicking on ABSTRACT on the issue’s contents page.

7 June 2023 in Jornal Brasileiro de Pneumologia
Verified
Journal Article
Open access
JLJoao Pedro Lima
Joao Pedro Lima
XCXiajing Chu
Xiajing Chu
Gordon H. GuyattGordon H. Guyatt
Gordon H. Guyatt
WTWimonchat Tangamornsuksan
Wimonchat Tangamornsuksan
Optimal clinical decision-making requires understanding of evidence regarding benefits, harms, and burdens of alternative management options. Rigorously conducted systematic reviews and meta-analyses offer accurate summaries of the evidence. However, such summaries may review only low-certainty evidence, in the process highlighting that no single decision is likely to be best for all patients. The Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach offers a systematic and transparent method for rating certainty of evidence in systematic reviews. In this paper, we will address the importance of assessing the certainty associated with bodies of evidence; explain how the GRADE system rates the certainty of evidence from systematic reviews; and present the GRADE evidence to decision framework for moving from evidence to strong or weak recommendations in clinical practice guidelines.